Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 2:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–19 of 19 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: DSP Clear all
Not listed No phase listed Observational Accepts healthy volunteers

Refractix DSP and TS Meter-DSP Measurement Comparison

NCT05717036
View directory record Official record
Conditions
Healthy
Interventions
Serum Total Protein Measurement with TS Meter-DSP and Refractix DSP
Device
Lead sponsor
Reichert, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Lauderhill, Florida
Source: ClinicalTrials.gov public record
Updated Feb 7, 2023 · Synced Sep 9, 2026, 2:53 AM EDT
Completed Phase 3 Interventional Results available

Evaluate the Neurological Effects of EryDex on Subjects With A-T

NCT06193200
View directory record Official record
Conditions
Ataxia Telangiectasia
Interventions
Dexamethasone sodium phosphate, Placebo
Drug · Other
Lead sponsor
Quince Therapeutics S.p.A.
Industry
Eligibility
6 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
4
States / cities
Los Angeles, California • Baltimore, Maryland • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Sep 9, 2026, 2:53 AM EDT
Terminated Phase 3 Interventional Results available

Extension Treatment Using EryDex System in Patients With AT Who Participated in the ATTeST-IEDAT-02-2015 Study

NCT03563053
View directory record Official record
Conditions
Ataxia Telangiectasia, Genetic Syndrome
Interventions
EryDex System
Combination Product
Lead sponsor
Quince Therapeutics S.p.A.
Industry
Eligibility
6 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
4
States / cities
Los Angeles, California • Baltimore, Maryland • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2024 · Synced Sep 9, 2026, 2:53 AM EDT
Completed Phase 2 Interventional

A 16-Week Study of Pirenzepine or Placebo to Treat HIV-Associated Distal Sensory Polyneuropathy in Patients With HIV

NCT05005078
View directory record Official record
Conditions
HIV Associated Polyneuropathy
Interventions
WST-057, Placebo
Drug
Lead sponsor
WinSanTor, Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Palm Springs, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2023 · Synced Sep 9, 2026, 2:53 AM EDT
Withdrawn Not applicable Interventional

Mobilizing Doulas to Empower Black Women in Post-partum Diabetes Prevention

NCT04406792
View directory record Official record
Conditions
Gestational Diabetes, Type2 Diabetes
Interventions
DPP only, Diabetes Prevention Program (DPP) online + doula divas
Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Sep 9, 2026, 2:53 AM EDT
Completed Phase 1Phase 2 Interventional

Safety and Efficacy Study of DSP-Visulex for the Treatment of Anterior Uveitis

NCT02309385
View directory record Official record
Conditions
Non-Infectious Anterior Uveitis
Interventions
8% Dexamethasone Sodium Phosphate - Visulex, 15% Dexamethasone Sodium Phosphate - Visulex, Prednisolone Acetate (1%) Eye Drops
Drug
Lead sponsor
Aciont Inc
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
6
States / cities
Cambridge, Massachusetts • Charlotte, North Carolina • Fargo, North Dakota + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Sep 9, 2026, 2:53 AM EDT
Withdrawn Not applicable Interventional

Diabetes Prevention and Education

NCT05769127
View directory record Official record
Conditions
Diabetes, Pre Diabetes, Fatty Liver, Body Weight Changes
Interventions
Diabetes Prevention Program (DPP), Diabetes Self-Management Training (DSMT)
Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 89 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Sep 9, 2026, 2:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Recovery and Survival of EryDex in Non-patient Volunteers

NCT02380924
View directory record Official record
Conditions
Healthy
Interventions
DSP loaded RBC using EryDex System, Sham treated RBC using the EryDex System
Drug
Lead sponsor
Quince Therapeutics S.p.A.
Industry
Eligibility
18 Years to 55 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jan 31, 2016 · Synced Sep 9, 2026, 2:53 AM EDT
Completed Phase 2 Interventional Results available

TLC399 (ProDex) in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO)

NCT03093701
View directory record Official record
Conditions
Retinal Vein Occlusion, Macula Edema
Interventions
TLC399 (ProDex)
Drug
Lead sponsor
Taiwan Liposome Company
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
20
States / cities
Phoenix, Arizona • Arcadia, California • Beverly Hills, California + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2021 · Synced Sep 9, 2026, 2:53 AM EDT
Terminated Phase 3 Interventional Results available

Open-Label Extension of EryDex Study IEDAT-04-2022

NCT06664853
View directory record Official record
Conditions
Ataxia Telangiectasia
Interventions
Dexamethasone sodium phosphate
Drug
Lead sponsor
Quince Therapeutics S.p.A.
Industry
Eligibility
6 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
5
States / cities
Los Angeles, California • Baltimore, Maryland • New Brunswick, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 9, 2026, 2:53 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Pacific Islander Physical Activity Project

NCT06523946
View directory record Official record
Conditions
Physical Inactivity
Interventions
Diabetes Prevention Program (DPP) (shortened)
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 9, 2026, 2:53 AM EDT
Completed Phase 3 Interventional Results available

Intra-Erythrocyte Dexamethasone Sodium Phosphate in Ataxia Telangiectasia Patients

NCT02770807
View directory record Official record
Conditions
Nervous System Disease, Genetic Syndrome
Interventions
EryDex Low dose DSP, EryDex High dose DSP, Pooled Placebo
Drug
Lead sponsor
Quince Therapeutics S.p.A.
Industry
Eligibility
6 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
4
States / cities
Los Angeles, California • Baltimore, Maryland • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated May 9, 2024 · Synced Sep 9, 2026, 2:53 AM EDT
Completed Phase 3 Interventional Results available

Extended and Controlled Release Liposomal Formulated Dexamethasone for Chronic Knee OA Pain

NCT04123561
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
TLC599, DSP, Normal Saline
Drug · Other
Lead sponsor
Taiwan Liposome Company
Industry
Eligibility
40 Years and older
Enrollment
504 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
41
States / cities
Birmingham, Alabama • Sheffield, Alabama • Phoenix, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2024 · Synced Sep 9, 2026, 2:53 AM EDT
Completed Not applicable Interventional

Acupuncture/Moxibustion (Acu/Moxa) for Distal Symmetric Peripheral Neuropathy (DSP) in HIV

NCT00826345
View directory record Official record
Conditions
Peripheral Neuropathy, HIV, AIDS, HIV Infections
Interventions
Acupuncture/Moxibustion
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 21, 2012 · Synced Sep 9, 2026, 2:53 AM EDT
Completed Not applicable Interventional

ObeSity and Jobs in SoCioeconomically Disadvantaged CommUnities: A Randomized CLinical Precision Public HealTh Intervention --The SCULPT-Job Study

NCT04709549
View directory record Official record
Conditions
Weight Maintenance, Weight Loss, Stress, Psychological, Job Stress, Diabetes Prevention, Obesity, Cardiovascular Risk Factor, Cardiovascular Diseases
Interventions
Diabetes Prevention Program + Job and Legal Services, Diabetes Prevention Program
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Sep 9, 2026, 2:53 AM EDT
Completed Not applicable Interventional Results available

Expert Guiding Technology to Help Individuals With Developmental Challenges Build Life and Vocational Skills

NCT04518358
View directory record Official record
Conditions
Autism Spectrum Disorder, Intellectual Disability
Interventions
Use of Expert Guiding Technology (GAINS) to Improve Live and Vocational Skills for Individuals with Developmental Challenges
Behavioral
Lead sponsor
John T. Nosek
Industry
Eligibility
Not listed
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Sep 9, 2026, 2:53 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Phase 2, Open Label, Pharmacokinetic (PK) Study of TLC599 in Subjects With Osteoarthritis of the Knee

NCT03754049
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
TLC599, DSP
Drug
Lead sponsor
Taiwan Liposome Company
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
7
States / cities
Phoenix, Arizona • Miami, Florida • Charleston, South Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2024 · Synced Sep 9, 2026, 2:53 AM EDT
Recruiting Phase 3 Interventional

An Efficacy and Safety Study of DFL24498 in the Treatment of AKC

NCT07395232
View directory record Official record
Conditions
Atopic Keratoconjunctivitis
Interventions
DFL24498, Vehicle, dexamethasone sodium phosphate (DSP) ophthalmic solution
Drug
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years to 65 Years
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
8
States / cities
Jacksonville, Florida • Miami, Florida • Morrow, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Sep 9, 2026, 2:53 AM EDT
Completed Not applicable Interventional

Preventing Diabetes

NCT05395377
View directory record Official record
Conditions
PreDiabetes
Interventions
Registered Dietitian/Nutritionist, Diabetes Prevention Program, Weight Watchers, Reimagined, DPP or RDN Counseling + Medication, Bariatric Surgery Evaluation
Behavioral · Other
Lead sponsor
Geisinger Clinic
Other
Eligibility
18 Years to 89 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Danville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 26, 2022 · Synced Sep 9, 2026, 2:53 AM EDT